NCT03322215: HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

NCT03322215
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic untreated brain metastases or leptomeningeal carcinomatosis that require treatment; Patients with a previous metastatic tumor biopsy reported to be both ER- & PR-negative (i.e. <1% for both) or HER2+ https://ClinicalTrials.gov/show/NCT03322215

Comments are closed.

Up ↑